Evidence map›Paper›PMID 32304937›Full record

ArticleBiomaterials2020

Redirecting extracellular proteases to molecularly guide radiosensitizing drugs to tumors.

Dina V Hingorani, Jessica L Crisp, Matthew K Doan, Maria F Camargo, Maryam A Quraishi, Joseph Aguilera, Mara Gilardi, Larry A Gross, Tao Jiang, Wei T Li and 5 more

Open access · hybridAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Biomaterials, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.1field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 22 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Peptide-Based Biomaterials as a Promising Tool for Cancer Radiotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025
    Review
  6. Review
  7. Article
  8. Review
  9. Review
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Chemical science · 2020
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 2 institutions in 1 country.

Dina V HingoraniDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
Jessica L CrispDepartment of Pharmacology, University of California San Diego, La Jolla, CA, 92093, USA.
Matthew K DoanDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
Maria F CamargoDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
Maryam A QuraishiDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
Joseph AguileraDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA.
Mara GilardiDepartment of Pharmacology, University of California San Diego, La Jolla, CA, 92093, USA.
Larry A GrossDepartment of Pharmacology, University of California San Diego, La Jolla, CA, 92093, USA.
Tao JiangDepartment of Pharmacology, University of California San Diego, La Jolla, CA, 92093, USA.
Wei T LiDivision of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California San Diego, La Jolla, CA, 92093, USA.
Weg M OngkekoDivision of Otolaryngology-Head and Neck Surgery, Department of Surgery, University of California San Diego, La Jolla, CA, 92093, USA.
Ezra E W CohenUC San Diego, Moores Cancer Center, La Jolla, CA, 92093, USA; Department of Medicine, Division of Hematology and Oncology, University of California San Diego, La Jolla, CA, 92093, USA.
J Silvio GutkindDepartment of Pharmacology, University of California San Diego, La Jolla, CA, 92093, USA; UC San Diego, Moores Cancer Center, La Jolla, CA, 92093, USA.
Stephen R AdamsDepartment of Pharmacology, University of California San Diego, La Jolla, CA, 92093, USA.
Sunil J AdvaniDepartment of Radiation Medicine and Applied Sciences, University of California San Diego, La Jolla, CA, 92093, USA; UC San Diego, Moores Cancer Center, La Jolla, CA, 92093, USA. Electronic address: sjadvani@ucsd.edu.
University of California, San Diego · USMoores Cancer Center

Funding

VIRAL MALIGNANCYP30CA023100 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI Jesse Nodora · 1985 to 2026
$124.9M
Elucidation and therapeutic exploitation of PAK mediated radioresistanceR37CA215081 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADVANI, SUNIL J · 2018 to 2024
$2.5M
Targeting the EGFR-PI3K/mTOR Signaling Circuitry: A Network-Based Approach for Oral Cancer Precision TherapyR01DE026870 · NIDCR · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI GUTKIND, JORGE SILVIO · 2018 to 2022
$2.3M
Restricting radiosensitization through ErbB targeted antibody drug conjugatesR21CA205765 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADVANI, SUNIL J · 2016 to 2017
$371k
Developing targeted activatable peptides to amplify radiosensitizer deliveryR03CA219744 · NCI · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADVANI, SUNIL J · 2017 to 2018
$155k
NCI NIH HHS P30 CA023100NCI NIH HHS R03 CA219744NCI NIH HHS R21 CA205765NCI NIH HHS R37 CA215081NIDCR NIH HHS R01 DE026870
6 · The paper itself

Abstract

Patients with advanced cancers are treated with combined radiotherapy and chemotherapy, however curability is poor and treatment side effects severe. Drugs sensitizing tumors to radiotherapy have been developed to improve cell kill, but tumor specificity remains challenging. To achieve tumor selectivity of small molecule radiosensitizers, we tested as a strategy active tumor targeting using peptide-based drug conjugates. We attached an inhibitor of the DNA damage response to antibody or cell penetrating peptides. Antibody drug conjugates honed in on tumor overexpressed cell surface receptors with high specificity but lacked efficacy when conjugated to the DNA damage checkpoint kinase inhibitor AZD7762. As an alternative approach, we synthesized activatable cell penetrating peptide scaffolds that accumulated within tumors based on matrix metalloproteinase cleavage. While matrix metalloproteinases are integral to tumor progression, they have proven therapeutically elusive. We harnessed these pro-tumorigenic extracellular proteases to spatially guide radiosensitizer drug delivery using cleavable activatable cell penetrating peptides. Here, we tested the potential of these two drug delivery platforms targeting distinct tumor compartments in combination with radiotherapy and demonstrate the advantages of protease triggered cell penetrating peptide scaffolds over antibody drug conjugates to deliver small molecule amine radiosensitizers.

Indexed as

Cell-Penetrating PeptidesRadiation-Sensitizing AgentsCell Line, TumorDrug Delivery SystemsHumansPeptide HydrolasesCell-Penetrating PeptidesPeptide HydrolasesRadiation-Sensitizing AgentsAntibody drug conjugatesCell penetrating peptidesRadiosensitizationRadiotherapyTargeted drug delivery

Identifiers

PMID32304937
PMCPMC7285923
OpenAlexW3015885882

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.